Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC versus FENOPROFEN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC versus FENOPROFEN CALCIUM.
DICLOFENAC vs FENOPROFEN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Oral: 50 mg twice daily or 75 mg twice daily; maximum 150 mg/day. Topical: apply 4 times daily. IM: 75 mg once daily.
Oral: 300-600 mg every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life ~2 h (diclofenac immediate-release); enterohepatic recirculation may produce secondary peaks. Clinical context: Short half-life requires multiple daily dosing for sustained effect.
Clinical Note
moderateDiclofenac + Gatifloxacin
"Diclofenac may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiclofenac + Rosoxacin
"Diclofenac may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiclofenac + Levofloxacin
"Diclofenac may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiclofenac + Trovafloxacin
"Diclofenac may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life is 2–3 hours; may be prolonged in elderly and patients with hepatic impairment.
Renal (65% as metabolites, <1% unchanged); biliary/fecal (35% as metabolites).
Primarily renal; approximately 90% of a dose is excreted in urine as glucuronide conjugates and unchanged drug; <2% excreted in feces.
Category D/X
Category C
NSAID
NSAID